Mural Oncology plc (NASDAQ:MURA) Short Interest Update

Mural Oncology plc (NASDAQ:MURA) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 396,800 shares, a decrease of 25.2% from the January 15th total of 530,200 shares. Based on an average trading volume of 206,900 shares, the days-to-cover ratio is currently 1.9 days. Approximately 2.6% of the shares of the stock are short sold.

Mural Oncology Stock Up 0.7 %

Shares of NASDAQ:MURA traded up $0.03 during midday trading on Friday, hitting $4.29. The stock had a trading volume of 67,600 shares, compared to its average volume of 182,120. Mural Oncology has a 1 year low of $2.87 and a 1 year high of $5.62. The stock has a 50 day moving average price of $3.70 and a two-hundred day moving average price of $3.52.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Mural Oncology in a research report on Monday, November 11th.

Institutional Investors Weigh In On Mural Oncology

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in shares of Mural Oncology by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock worth $595,000 after acquiring an additional 4,731 shares during the period. Northern Trust Corp increased its position in Mural Oncology by 22.0% during the fourth quarter. Northern Trust Corp now owns 39,966 shares of the company’s stock worth $129,000 after acquiring an additional 7,197 shares during the period. FMR LLC increased its position in Mural Oncology by 124.7% during the third quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after acquiring an additional 11,423 shares during the period. Commerce Bank bought a new stake in Mural Oncology in the 3rd quarter valued at $39,000. Finally, Jane Street Group LLC bought a new stake in shares of Mural Oncology in the 4th quarter worth about $68,000. 80.21% of the stock is currently owned by hedge funds and other institutional investors.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.